• Bang-Shuo Zhang, Yong-Ping Chen, Jing-Long Lv, and Yi Yang.
• Department of Hematology, Chongqing Three Gorges Central Hospital, 404000, China.
• J Coll Physicians Surg Pak. 2019 Jul 1; 29 (7): 631-634.

ObjectiveTo compare the efficacy of nilotinib and imatinib in the treatment of chronic myeloid leukemia (CML).Study DesignAnalytical study.Place And Duration Of StudyDepartment of Hematology, Chongqing Three Gorges Central Hospital, China, from January 2016 to January 2018.MethodologyEighty patients with CML were randomly divided into the nilotinib group (treated with nilotinib) and the imatinib group (treated with imatinib), 40 patients in each group. The therapeutic effects of the two groups of patients were compared.ResultsAfter months of treatment, the neutrophilic granulocytes and neutrophilic metamyelocyte, serum interleukin (IL)-6 and IL-8 and α1-acid glycoprotein (AGP) levels in nilotinib group were lower than those in imatinib group (p=0.002, p<0.001, p=0.027, p=<0.001 and p=0.001, respectively); the proportion of patients with BCR-ABLIS <10% in nilotinib group and the proportion of patients with BCR-ABLIS <0.0032% were higher than those in imatinib group (p=0.032 and 0.043, respectively). During treatment period, there was no significant difference in the incidence of adverse reactions such as mild liver damage, nausea and vomiting, rash, musculoskeletal pain and edema between two groups (p = 0.556, 0.396, 0.576, 0.775 and 0.390, respectively).ConclusionNilotinib is superior to imatinib in the treatment of CML. There is no significant difference in the safety of the two drugs, and the adverse reactions can be tolerated.

25 keywords...

hide…